NCT06716151View on ClinicalTrials.gov

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

November 20, 2025

Study Completion Date

November 20, 2025

Conditions
Healthy
Interventions
DRUG

HB0034

Recombinant Humanized Anti-IL-36R Monoclonal antibody

DRUG

HB0034 matching placebo

HB0034 matching Palcebo

Trial Locations (1)

Unknown

RECRUITING

Central Hospital affiliated to Shandong First Medical University, Jinan

All Listed Sponsors
lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY